Zeus Capital acted as Nominated Adviser and Broker to Quantum Pharma plc on its £15m fundraise
Zeus Capital recently acted as Nominated Adviser and Joint Broker to Burnopfield-based Quantum Pharma on its £15m institutional fundraise.
Quantum Pharma, the service-led niche pharmaceutical, developer and supplier to the health and care sectors, predominantly in the UK, recently announced a proposed £15m fund raise. The funds will be used to reduce bank borrowings and provide additional working capital.
The core Specials Division remains the focus of the group’s cash generation and is the leading supplier of Specials in the UK market. Quantum’s Niche Pharmaceuticals Division has been re-prioritised towards developing better performing core unlicensed-to-licensed products.
Chris Rigg, Chief Executive Officer and Chief Financial Officer at Quantum Pharma commented:
"The proceeds of the placing will ensure we are in the best possible position to deliver future growth and opportunities across the Group, by placing us on a sound financial footing to drive forward a simplified business centring on maximising our core specials platform and increasing our focus on delivering our unlicensed to licensed programme.”
Dominic Wilson - Head of Healthcare sales, Zeus Capital, said:
“We were delighted to help secure £15m of new capital for Quantum Pharma, attracting strong support from existing shareholders and some new institutional investors. This successful funding is a clear endorsement of the business and the management team, now in place, to take the business forward. Quantum’s team now has the capital structure in place to deliver on plan.”